95% response rate found in preliminary analysis of Epcoritamab for untreated follicular lymphoma patients, with reduced CRS rate, at Best of ASCO 2022.
95% overall response rate found in preliminary analysis of investigational Epcoritamab (DuoBody CD3xCD20) combination for previously untreated follicular lymphoma patients. C1 OPT of EPCORE NHL-1 study showed 49% CRS rate, down from 66% in pivotal cohort, with no Grade 3+ CRS and no ICANS reported. Data presented at Best of ASCO 2022.
June 02, 2024
3 Articles